論文－馬場 英司
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT):
Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz HJ, Goldberg RM, Sargent DJ, Cihon F, Cupit L, Wagner A, Laurent D; CORRECT Study Group.
an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 26;381:303-12, 2013
Phase I study of bevacizumab combined with irinotecan and S-1 as second-line chemotherapy in patients with advanced colorectal cancer.
Kusaba H, Esaki T, Kishimoto J, Uchino K, Arita S, Kumagai H, Mitsugi K, Akashi K, Baba E.
Cancer Chemother Pharmacol. 71:29-34, 2013
Human Nanog pseudogene8 promotes the proliferation of gastrointestinal cancer cells.
Uchino K, Hirano G, Hirahashi M, Isobe T, Shirakawa T, Kusaba H, Baba E, Tsuneyoshi M, Akashi K:
Exp Cell Res 318:1799-807,2012
Phase II Study of Modified CPT-11 and Bolus 5-FU/l-Leucovorin in Japanese Metastatic Colorectal Cancer Patients.
Baba E, Fujishima H, Makiyama A, Uchino K, Tanaka R, Esaki T, Kusaba H, Mitsugi K, Nakano S, Akashi K:
Advances in Therapy 29:287-96, 2012
Human STEAP3 maintains tumor growth under hypoferric condition.
Isobe T, Baba E, Arita S, Komoda M, Tamura S, Shirakawa T, Ariyama H, Takaishi S, Kusaba H, Ueki T, Akashi K:
Exp Cell Res 317:2582-91, 2011
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial
Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK, ToGA Trial Investigators.
Lancet 28;376:687-97, 2010
Phase I/II study of a 3-week cycle of irinotecan and S-1 in patients with advanced colorectal cancer.
Kusaba H, Esaki T, Futami K, Tanaka S, Fujishima H, Mitsugi K, Sakai K, Ariyama H, Tanaka R, Kinugawa N, Ueki T, Mibu R, Baba E, Nakano S, Akashi K:
Cancer Sci 101:2591-5, 2010
Oxaliplatin-induced allergic reaction in patients with colorectal cancer in Japan.
Shibata Y, Ariyama H, Baba E, Takii Y, Esaki T, Mitsugi K, Tsuchiya T, Kusaba H, Akashi K, Nakano S:
Int J Clin Oncol 14(5), 397-401, 2009
Phase I Study of the Sequential Administration of S-1 and Cisplatin for Metastatic Gastric Cancer.
Baba E, Fujishima H, Kusaba H, Esaki T, Ariyama H, Kato K, Tanaka R, Mitsugi K, Shibata Y, Harada M, Nakano S:
Anticancer Res 29(5), 1727-32, 2009
B cell activation regulates exosomal HLA production.
Arita S, Baba E, Shibata Y, Niiro H, Shimoda S, Isobe T, Kusaba H, Nakano S, Harada M:
Eur J Immunol 38(5): 1423-1434, 2008
Infusional 5-fluorouracil and cisplatin as first-line chemotherapy in patients with carcinoma of unknown primary site.
Kusaba H, Shibata Y, Arita S, Ariyama H, Baba E, Mitsugi K, Harada M, Nakano S:
Med Oncol 24(2): 259-264, 2007
Gefitinib, a selective EGFR tyrosine kinase inhibitor, induces apoptosis through activation of Bax in human gallbladder adenocarcinoma cells.
Ariyama H, Qin B, Baba E, Tanaka R, Mitsugi K, Harada M, Nakano S:
J Cell Biochem 97(4): 724-734, 2006
In vitro schedule-dependent interaction between paclitaxel and oxaliplatin in human cancer cell lines.
Tanaka R, Ariyama H, Qin B, Takii Y, Baba E, Mitsugi K, Harada M, Nakano S:
Cancer Chemother Pharmacol 55(6): 595-601, 2005
Phase I study of CPT-11 and bolus 5-FU/ l-leucovorin in patients with metastatic colorectal cancer.
Fujishima H, Kikuchi I, Miyanaga O, Ueda A, Baba E, Mitsugi K, Harada M, Nakano S:
Int J Clin Oncol 9(2): 92-97, 2004
Cyclosporin-A enhances docetaxel-induced apoptosis through inhibition of nuclear factor-kappaB activation in human gastric carcinoma cells.
Nakahara C, Nakamura K, Yamanaka N, Baba E, Wada M, Matsunaga H, Noshiro H, Tanaka M, Morisaki T, Katano M:
Clin Cancer Res 9(14): 5409-5416, 2003
Dysfunctional and short-lived subsets in monocyte-derived dendritic cells from patients with advanced cancer.
Onishi H, Morisaki T, Baba E, Kuga H, Kuroki H, Matsumoto K, Tanaka M, Katano M:
Clin Immunol 105(3): 286-295, 2002
Unique monoclonal antibody recognizing the third extracellular loop of CXCR4 induces lymphocyte agglutination and enhances human immunodeficiency virus type 1-mediated syncytium formation and productive infection.
Tanaka R, Yoshida A, Murakami T, Baba E, Lichtenfeld J, Omori T, Kimura T, Tsurutani N, Fujii N, Wang ZX, Peiper SC, Yamamoto N, Tanaka Y:
J Virol 75(23): 11534-11543, 2001
Functional CD4 T cells after intercellular molecular transfer of OX40 ligand.
Baba E, Takahashi Y, Lichtenfeld J, Tanaka R, Yoshida A, Sugamura K, Yamamoto N, Tanaka Y:
J Immunol 167(2): 875-883, 2001
N-linked carbohydrate on human leukocyte antigen-C and recognition by natural killer cell inhibitory receptors.
Baba E, Erskine R, Boyson JE, Cohen GB, Davis DM, Malik P, Mandelboim O, Reyburn HT, Strominger JL:
Hum Immunol 61(12): 1202-18, 2000
Biotinylation of class I MHC molecules abrogates recognition by W6/32 antibody.
Malik P, Baba E, Strominger JL:
Tissue Antigens 53(6): 576-579, 1999
The transmembrane sequence of human histocompatibility leukocyte antigen (HLA)-C as a determinant in inhibition of a subset of natural killer cells.
Davis DM, Mandelboim O, Luque I, Baba E, Boyson J, Strominger JL:
J Exp Med 189(8): 1265-1274, 1999
The association of antibodies against human T cell lymphotropic virus type I (HTLV-I) pX gene mutant products with HTLV-I-associated myelopathy/tropical spastic paraparesis.
Suzuki J, Kira J, Baba E, Nakamura M, Koyanagi Y, Nakamura T, Kawano Y, Yamasaki K, Shirabe S, Hatano N, Hayashi K, Yamamoto N, Kobayashi T:
J Infect Dis 173(5): 1115-1122, 1996
A peptide-based human T cell leukemia virus type I vaccine containing T and B cell epitopes that induces high titers of neutralizing antibodies.
Baba E, Nakamura M, Ohkuma K, Kira J, Tanaka Y, Nakano S, Niho Y:
J Immunol 154(1): 399-412, 1995
Multiple neutralizing B-cell epitopes of human T-cell leukemia virus type 1 (HTLV-1) identified by human monoclonal antibodies. A basis for the design of an HTLV-1 peptide vaccine.
Baba E, Nakamura M, Tanaka Y, Kuroki M, Itoyama Y, Nakano S, Niho Y:
J Immunol 151(2): 1013-1024, 1993